La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Plus Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Plus Therapeutics..

Plus Therapeutics (NASDAQ:PSTV) Azioni, Catena delle Opzioni

PLUS THERAPEUTICS INC

Plus Therapeutics

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Shanghai,,China,-,June,29,,2023:,Saic,Roewe,Feifan,F7

Tech

BPMC

CRDO

PSTV

SAIC

Tra utili societari, un&#39;acquisizione miliardaria e movimenti after-hours: alcune storie pronte a sfidare il trend di mercato.

Futures in rosso: 5 titoli sotto la lente d&#39;ingrandimento oggi

Plus Therapeutics Inc

POSTAL SVGS CHINA UNS/ADR by Postal Svgs Bk of China Ltd.

Postal Savings Bank Of China Co Ltd

Health Care

Press Releases

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Earnings

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

News

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Contracts

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

ABVC BioPharma

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

OKYO Pharma

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Sutro Biopharma

XBiotech

X4 Pharmaceuticals

Ascendiant Capital

D. Boral Capital

Maxim Group

HC Wainwright & Co.

Screenshot 2024-03-29 at 1.10.09 AM

Biotech

General

This Biotech Is Creating Targeted Radiotherapuetics For Some Of The Deadliest Cancers

Comments

Plus Therapeutics

Plus Therapeutics (PSTV) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO